MedTrace Logo

Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline

NCT00506415 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1584

Last updated 2012-09-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to support the optimal use of rivastigmine patch in long-term treatment of Alzheimer's Disease in patients demonstrating functional and cognitive decline at the target maintenance dose of rivastigmine patch 10 cm\^2.

Conditions

  • Alzheimer Disease

Interventions

DRUG

Rivastigmine 5 cm^2

5 cm\^2 transdermal patch

DRUG

Rivastigmine 10 cm^2

10 cm\^2 transdermal patch.

DRUG

Rivastigmine 15 cm^2

15 cm\^2 transdermal patch.

DRUG

Placebo to 15 cm^2 patch

Placebo of rivastigmine transdermal patch 15 cm\^2.

DRUG

Placebo to 10 cm^2 patch

Placebo of rivastigmine transdermal patch 10 cm\^2.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • United States
  • Canada
  • France
  • Germany
  • Italy
  • Spain
  • Switzerland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00506415 on ClinicalTrials.gov